Sanofi and AstraZeneca's preventive RSV therapy appears safe: FDA staff

Sanofi and AstraZeneca's preventive RSV therapy appears safe: FDA staff The companies are seeking the FDA's approval for use of the therapy in infants and children up to 24 months of age to protect them against lower respiratory tract disease that could cause pneumonia and bronchiolitis. https://ift.tt/JCfclTF